161 results
424B5
AGRX
Agile Therapeutics Inc
23 Feb 24
Prospectus supplement for primary offering
4:57pm
to the Warrant Exercise Agreement is expected to occur on or about February 26, 2024, subject to satisfaction of customary closing conditions. The Company
424B5
AGRX
Agile Therapeutics Inc
23 Feb 24
Prospectus supplement for primary offering
4:55pm
to the Warrant Exercise Agreement is expected to occur on or about February 26, 2024, subject to satisfaction of customary closing conditions. The Company
8-K
EX-4.3
jipq1xe7pox7g7dy5r
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-4.2
oc3te
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-99.1
u5ug5 j2x6
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-4.1
joj4s k5udckk
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-10.1
4pw7k9qx6 f4p4j
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-10.1
mbx2a6
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm